Key Features:
- High Sensitivity: The cell line offers high signal-to-background with over 500-fold induction in luciferase activity, ensuring accurate and reproducible results in CREB pathway studies.
- Sensitive and Quantitative: The luciferase reporter assay provides a direct and reliable readout of CREB activation, enabling precise measurement of pathway activity.
- Versatile Applications: Co-expression of GLP-1R and a CRE-responsive luciferase reporter mimics endogenous signaling cascades following GLP-1R activation. Suitable for screening applications and dose-response studies of GLP-1R-targeting compounds.
- Stable Integration: Established via co-transfection with GLP1R and CRE-luciferase constructs, followed by antibiotic selection and functional screening with Danuglipron and Exendin-4.
The GLP-1R/CREB Luciferase Reporter HEK293 Stable Cell Line is derived from human embryonic kidney cells and stably expresses glucagon-like peptide-1 receptor (GLP-1R) alongside a firefly luciferase reporter gene under the control of the cAMP response element-binding protein (CREB) response element. This dual-expression cell line is an ideal tool for monitoring the intracellular signaling events triggered by GLP1R activation.
The functionality of GLP-1R/CRE Luciferase Reporter HEK293 Cell Line was validated in dose-response assays using the peptide agonists Glucagon-like peptide 1 (7-37), Glucagon-like peptide 1 (7-36) amide, Exendin-4, Semaglutide and Tirzepatide.
This versatile cell line serves as a powerful in vitro tool for both basic research and translational applications in endocrinology, pharmacology, and metabolic disease research.
GLP-1R/CRE Luciferase Reporter HEK293 Stable Cell Line (2 vials)
Q: How does the reporter system work?
A: Upon ligand binding, GLP-1R activates the Gs–cAMP pathway, leading to phosphorylation and activation of CREB. Activated CREB binds to CRE elements upstream of the luciferase reporter gene, resulting in a robust, dose-dependent luminescent signal.
Q: What ligands can be used to validate the assay?
A: The cell line responds strongly to known GLP-1R agonists, including GLP-1 peptides and small molecule like Exendin-4.
Q: What are the key advantages of using this stable cell line?
A: This GLP-1R/CREB reporter stable cell line offers competitive pricing, delivers strong, dose-dependent induction with a high signal-to-background ratio, and demonstrates robust responsiveness to both peptide ligands and small-molecule compounds, making it a reliable and cost-effective solution for GLP-1R drug discovery and screening applications.